AstraZeneca admitted for the first time in court that the Covid vaccine it developed could cause a rare side effect, according to a report. Telegraph. A pharmaceutical company is facing a class-action lawsuit after its vaccine allegedly caused the deaths and serious injuries of several people.
The company has already acknowledged that the vaccine may cause blood clots and low platelet counts.
The first case was reported last year by Jamie Scott, a father of two who was left with permanent brain damage after a blood clot and bleeding on the brain prevented him from working after being vaccinated in April 2021.
A total of 51 cases have been opened, with victims and their families demanding compensation amounting to more than 100 million euros.
Lawyers for victims have argued that the AstraZeneca-Oxford vaccine is “defective” and that its effectiveness has been “grossly exaggerated” – claims AstraZeneca vehemently denies.
Scientists first identified a link between the vaccine and a new disease called vaccine-induced immune thrombocytopenia and thrombosis (VITT) in March 2021, shortly after Covid-19 vaccinations began.
The company notes that the vaccine information was updated in April 2021 with UK regulatory approval to include “the possibility that the AstraZeneca-Oxford vaccine may, in very rare circumstances, trigger” TTS (thrombotic syndrome with thrombocytopenia).
Independent research shows the AstraZeneca vaccine has been incredibly effective in fighting the pandemic, saving more than six million lives worldwide in its first year of use.
The World Health Organization said the vaccine was “safe and effective for all people aged 18 years and over” and the side effects that prompted the lawsuit were “very rare.”
Author: morning Post
Source: CM Jornal

I’m Dave Martin, and I’m an experienced journalist working in the news industry. As a part of my work, I write for 24 News Reporters, covering mostly sports-related topics. With more than 5 years of experience as a journalist, I have written numerous articles on various topics to provide accurate information to readers.